Expression and clinical significance of TFF3 and HER2 in adenocarcinoma of esophagogastric junction

ZHANG Xiao-hui; WANG Hai-wei; TIAN Yun-xiao; YANG Jian-hua; SUN Ying; YUAN Yan-long

doi:10.11659/jjssx.09E022110

您当前的位置：

首页 >

文章列表页 >

Expression and clinical significance of TFF3 and HER2 in adenocarcinoma of esophagogastric junction

Clinical Research | 更新时间：2023-07-17

- Expression and clinical significance of TFF3 and HER2 in adenocarcinoma of esophagogastric junction
- JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY Vol. 32, Issue 7, Pages: 628-632(2023)
- 作者机构：
  
  邯郸市中心医院病理科，河北邯郸 056001
- 作者简介：
- 基金信息：
- DOI：10.11659/jjssx.09E022110
  CLC： R735.1
- Published：25 July 2023，
  
  Received：19 September 2022，
扫描看全文
张小辉,王海伟,田云霄等.TFF3和HER2在食管胃交界部腺癌中的表达及临床意义[J].局解手术学杂志,2023,32(07):628-632.

ZHANG Xiao-hui,WANG Hai-wei,TIAN Yun-xiao,et al.Expression and clinical significance of TFF3 and HER2 in adenocarcinoma of esophagogastric junction[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2023,32(07):628-632.
张小辉,王海伟,田云霄等.TFF3和HER2在食管胃交界部腺癌中的表达及临床意义[J].局解手术学杂志,2023,32(07):628-632. DOI： 10.11659/jjssx.09E022110.

ZHANG Xiao-hui,WANG Hai-wei,TIAN Yun-xiao,et al.Expression and clinical significance of TFF3 and HER2 in adenocarcinoma of esophagogastric junction[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2023,32(07):628-632. DOI： 10.11659/jjssx.09E022110.

摘要

目的

探讨三叶因子3（TFF3）及人表皮生长因子受体2（HER2）在食管胃交界部腺癌(AEG)组织中的表达及临床意义。

方法

选取140例行手术切除的AEG患者，采用免疫组化法检测AEG组织中TFF3的表达情况，免疫组化法及免疫荧光法检测HER2的表达情况，分析二者表达的差异及其与临床病理特征和预后的关系。

结果

在AEG组织中，TFF3的阳性表达率为51.43%，HER2的阳性表达率为15.00%。TFF3阳性多见于Laurén分型为弥漫型、出现淋巴结转移的患者。HER2阳性多见于Laurén分型为肠型的患者。HER2阴性患者TFF3阳性表达率高于阳性患者（

=5.167，

=0.023）。

Kaplan

Meier

生存曲线分析显示，TFF3表达会影响AEG患者生存率，TFF3阳性的AEG患者生存率明显低于TFF3阴性患者。

Cox

回归分析结果显示，淋巴结转移、TNM分期较晚及TFF3阳性表达是AEG独立预后的危险因素（

0.05）。

结论

TFF3阳性提示患者预后差，是影响AEG预后的独立危险因素；HER2的表达不影响AEG的预后。TFF3及HER2是AEG发生发展的重要因子，二者可能在AEG的发生发展中相互作用，是否可以作为治疗靶标有待进一步研究。

Abstract

Objective

To investigate the expression and clinical significance of trefoil factor-3 （TFF3） and human epidermal growth factor receptor 2 （HER2） in adenocarcinoma of esophagogastric junction （AEG） tissue.

Methods

A total of 140 AEG patients who underwent surgical resection were selected， and the expression of TFF3 in AEG tissues was detected by immunohistochemistry， and the expression of HER2 was detected by immunohistochemistry and immunofluorescence. The differences in expression between the two and the relationship with clinicopathological features and prognosis were analyzed.

Results

In AEG tissues， the positive expression rate of TFF3 was 51.43%， and the positive expression rate of HER2 was 15.00%. Positive TFF3 is more common in patients with diffuse Laurén classification and lymph node metastasis. Positive HER2 is more common in patients with Laurén's intestinal type. The positive expression rate of TFF3 in HER2 negative patients was higher than that in HER2 positive patients （

=5.167，

=0.023）.

Kaplan-Meier

survival curve analysis showed that TFF3 expression can affect the survival rate of AEG patients， and the survival rate of AEG patients with positive TFF3 was significantly lower than that of TFF3 negative patients.

Cox

regression analysis showed that lymph node metastasis， late TNM staging， and TFF3 positive expression were the independent prognostic risk factors for AEG （

0.05）.

Conclusion

Positive TFF3 indicates poor prognosis in patients and is an independent risk factor affecting the prognosis of AEG. The expression of HER2 does not affect the prognosis of AEG. TFF3 and HER2 are important factors in the occurrence and development of AEG， and they may interact with each other in the occurrence and development of AEG. Further research is needed to determine whether they can be used as therapeutic targets.

关键词

HER2TFF3食管胃交界部腺癌临床意义临床病理特征

Keywords

HER2TFF3esophagogastric junctionadenocarcinomaclinical significanceclinicopathological features

references

Siewert JR，Feith M，Stein HJ.Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction：relevance of atopographic-anatomic subclassification［J］.J Surg Oncol，2005，90（3）：139-146.doi：10.1002/JSO.20218http://dx.doi.org/10.1002/JSO.20218.

李飞，宋媛，李芳，等.食管胃交界部腺癌SiewertⅠ型和Ⅱ型胸外科手术治疗效果及预后研究［J］.中国癌症杂志，2021，31（2）：143-150.doi：10.19401/j.cnki.1007-3639.2021.02.009http://dx.doi.org/10.19401/j.cnki.1007-3639.2021.02.009.

Im S，Yoo C，Jung JH，et al.Reduced expression of TFF1 and increased expression of TFF3 in gastric cancer：correlation with clinicopathological parameters and prognosis［J］.Int J Med Sci，2013，10（2）：133-140.doi：10.7150/IJMS.5500http://dx.doi.org/10.7150/IJMS.5500.

吕晓双，罗斌.抗HER-2治疗的耐药机制及对策的研究进展［J］.现代肿瘤医学，2022，30（3）：529-534.doi：10.3969/j.issn.1672-4992.2022.03.032http://dx.doi.org/10.3969/j.issn.1672-4992.2022.03.032.

《胃癌HER2检测指南（2016版）》专家组.胃癌HER2检测指南（2016版）［J］.中华病理学杂志，2016，45（8）：528-532.doi：10.3760/cma.j.issn.0529-5807.2016.08.00http://dx.doi.org/10.3760/cma.j.issn.0529-5807.2016.08.00.

D'Journo XB.Clinical implication of the innovations of the 8th edition of the TNM classification for esophageal and esophago-gastric cancer［J］.J Thorac Dis，2018，10（Suppl 22）：S2671-S2681.doi：10.21037/jtd.2018.03.182http://dx.doi.org/10.21037/jtd.2018.03.182.

李浩淼，孙海波，郑燕，等.AJCC/UICC第八版食管及食管胃交界部癌TNM分期解读及中文版主要内容［J］.中国胸心血管外科临床杂志，2017，24（2）：87-92.doi：10.7507/1007-4848.201612067http://dx.doi.org/10.7507/1007-4848.201612067.

Li Y，Sun Z，Liu K，et al.Prognostic significance of the co-expression of nucleophosmin and trefoil factor 3 in postoperative gastric cancer patients［J］.Mol Clin Oncol，2014，7（2）：1055-1061.doi：10.3892/mco.2014.351http://dx.doi.org/10.3892/mco.2014.351.

Kjellev S.The trefoil factor family-small peptides with multiple functionalities［J］.Cell Mol Life Sci，2009，66（8）：1350-1369.doi：10.1007/s00018-008-8646-5http://dx.doi.org/10.1007/s00018-008-8646-5.

Perry JK，Kannan N，Grandison PM，et al.Are trefoil factors oncogenic？［J］.Trends Endocrinol Metab，2008，19（2）：74-81.doi：10.1016/j.tem.2007.10.003http://dx.doi.org/10.1016/j.tem.2007.10.003.

胡婷，汪子书.胃癌组织中TFF3和PDGFR的表达及临床意义［J］.中华全科医学，2018，16（12）：1989-1991.doi：10.7666/d.D666683http://dx.doi.org/10.7666/d.D666683.

Rivat C，Rodrigues S，Bruyneel E，et al.Implication of STAT3 signaling in human colonic cancer cells during intestinal trefoil factor 3 （TFF3）--and vascular endothelial growth factor-mediated cellular invasion and tumor growth［J］.Cancer Res，2005，65（1）：195-202.

顾建春.HER2和TFF3在胃癌中的表达及其临床意义［D］.上海：第二军医大学，2018.

Gu J，Zheng L，Zhang L，et al.TFF3 and HER2 expression and their correlation with survival in gastric cancer［J］.Tumor Biology，2015，36（4）：3001-3007.doi：10.1007/s13277-014-2933-6http://dx.doi.org/10.1007/s13277-014-2933-6.

Yarden Y，Pines G.The ERBB network：at last，cancer therapy meets systems biology［J］.Nat Rev Cancer，2012，12：553-563.doi：10.1038/nrc3309http://dx.doi.org/10.1038/nrc3309.

雷瑞雪，苗兰芳.HER2阳性胃腺癌临床病理分析［J］.中国实用医刊，2018，45（8）：29-31.doi：10.3760/cma.j.issn.1674-4756. 2018.08.009http://dx.doi.org/10.3760/cma.j.issn.1674-4756.2018.08.009.

Kim WH，Gomez-Izquierdo L，Vilardell F，et al.HER2 status in gastric and gastroesophageal junction cancer：results of the large，multinational HER-EAGLE study［J］.Appl Immunohistochem Mol Morphol，2018，26（4）：239-245.doi：10.1097/PAI.0000000000000423http://dx.doi.org/10.1097/PAI.0000000000000423.

黄丹，李增山，樊祥山，等.中国人40842例胃腺癌HER2多中心检测结果分析［J］.中华病理学杂志，2018，47（11）：822-826.doi：10.3760/cma.j.issn.0529-5807.2018.11.002http://dx.doi.org/10.3760/cma.j.issn.0529-5807.2018.11.002.

陈键，何裕隆.食管胃结合部腺癌的靶向治疗进展［J］.消化肿瘤杂志（电子版），2019，11（4）：317-324.doi：10.3969/j.issn. 1674-7402.2019.04.001http://dx.doi.org/10.3969/j.issn.1674-7402.2019.04.001.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical significance of FEN1 regulating the occurrence and prognosis of hepatocellular carcinoma

Expression and clinical significance of long noncoding RNA metastasisassociated lung adenocarcinoma transcript 1 in oral squamous cell carcinoma

Clinical significance of BRAF V600E mutation in Marjolin ulcer squamous cell carcinoma

Expression of HMGB1 and TLR2 in serum of patients with secretory otitis media and its clinical significance

Related Author

ZHAO Jian-hong

CEN Hong-bing

YANG Zhi-yong

CHEN Feng

ZHANG Peng

ZHAO Junwei

AN Hongli

ZHENG Shuping

Related Institution

Department of Pathology，Huanggang Central Hospital Affiliated to Changjiang University

Department of Oncology，Huanggang Central Hospital Affiliated to Changjiang University

Department of Hepatobiliary Surgery，Huanggang Central Hospital Affiliated to Changjiang University

Operating Room,Ninth Hospital of Tangshan, Tangshan Hebei China

Department of Stomatology,Tangshan Union Medical College Hospital

⁰